Monish D. Patolawala
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Biogen sees kidney therapy progress and rating upgrade. Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
3M to challenge $1.4B Australian PFAS lawsuit ahead of Q3 earnings. 3M is preparing to challenge Australia's $1.4 billion PFAS contamination lawsuit, a major legal development for the company. At the same time, market participants are looking ahead to 3M's upcoming third-quarter earnings, with Wall Street projections offering insights into key metrics. The stock is currently trading within its 52-week range, with an average analyst target of $186.15.
Transaction History
| ADM | ▼ Sell | Tax Withholding | 6,720 | $533K | 8/3/2026 | View on chart |
| BIIB | ▲ Buy | Grant | 1,505 | $0 | 6/9/2026 | View on chart |
| ADM | ▼ Sell | Tax Withholding | 9,161 | $637K | 2/13/2026 | View on chart |
| ADM | ▲ Buy | Grant | 40,000 | $0 | 2/12/2026 | View on chart |
| ADM | ▼ Sell | Tax Withholding | 34,447 | $2.3M | 2/2/2026 | View on chart |
| ADM | ▼ Sell | Tax Withholding | 25,236 | $1.4M | 8/1/2025 | View on chart |
| BIIB | ▲ Buy | Grant | 2,370 | $0 | 6/17/2025 | View on chart |
| ADM | ▲ Buy | Grant | 60,819 | $0 | 2/13/2025 | View on chart |
| ADM | ▼ Sell | Tax Withholding | 18,312 | $938K | 2/3/2025 | View on chart |
| ADM | ▲ Buy | Grant | 211,310 | $0 | 8/1/2024 | View on chart |
| MMM | ▼ Sell | Tax Withholding | 13,740 | $1.4M | 6/28/2024 | View on chart |
| MMM | ▲ Buy | Option Exercise | 30,131 | $3.1M | 6/28/2024 | View on chart |
| BIIB | ▲ Buy | Grant | 1,340 | $0 | 6/21/2024 | View on chart |
| MMM | ▲ Buy | Grant | 10,196 | $0 | 2/5/2024 | View on chart |
| MMM | ▼ Sell | Tax Withholding | 4,146 | $0 | 2/5/2024 | View on chart |
| MMM | ▲ Buy | Option Exercise | 6,128 | $581K | 2/2/2024 | View on chart |
| MMM | ▼ Sell | Tax Withholding | 1,893 | $180K | 2/2/2024 | View on chart |
| MMM | ▲ Buy | Option Exercise | 6,013 | $602K | 6/30/2023 | View on chart |
| MMM | ▼ Sell | Tax Withholding | 2,742 | $274K | 6/30/2023 | View on chart |
| MMM | ▲ Buy | Grant | 12,626 | $0 | 2/6/2023 | View on chart |
| MMM | ▼ Sell | Tax Withholding | 5,788 | $0 | 2/6/2023 | View on chart |
| MMM | ▲ Buy | Option Exercise | 6,013 | $773K | 7/5/2022 | View on chart |
| MMM | ▼ Sell | Tax Withholding | 2,664 | $342K | 7/5/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
ADM Faces Q3 Earnings and Sweetener Market Weakness
Archer-Daniels-Midland is approaching its Q3 2026 earnings report amid concerns about weakness in its sweetener business. Analysts are debating whether performance in the ethanol sector can offset these headwinds. The company’s dividend reliability remains a key focus for investors, though cyclical uncertainty persists.
ADM Faces Q3 Earnings and Sweetener Market Weakness. Archer-Daniels-Midland is approaching its Q3 2026 earnings report amid concerns about weakness in its sweetener business. Analysts are debating whether performance in the ethanol sector can offset these headwinds. The company’s dividend reliability remains a key focus for investors, though cyclical uncertainty persists.